CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project seeks to improve cancer treatment by developing targeted radiotherapy using alpha-emitting radionuclides. It focuses on creating advanced delivery systems that can effectively target small tumors and isolated cancer cells.
This project aims at improving drug delivery to cancer cells by developing targeted radiotherapy with alpha-emitting radionuclides.
Alpha particles emitted by radionuclides have short tracks (about 100 microns) in body tissues.
As a result, they should be most appropriate to treat small-size tumours and isolated cancer cells.
This project proposes the development of improved vectors and targeting technology based on specific targeting agents (recombinant antibody fragments and synthetic peptides…
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Switzerland, Basel
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Germany, Muenchen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Hannover
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
UGOT - GOETEBORGS UNIVERSITET/UNIVERSITY OF GOTHENBURG
Sweden, Goeteborg
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
